Congressman Cleaver has fought to lower the cost of prescription drugs so families do not have to choose between their medications and their groceries.
Keep fighting to lower the cost of prescription drugs.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
Congressional Record Index entry for Emanuel Cleaver lists H.R. 7391 and H.R. 4317 among the bills associated with him in the 119th Congress, 2nd Session. H.R. 7391 is the Community Health Center Drug Pricing Protection Act, and another indexed item is the Pharmacy Benefit Manager (PBM) Reform Act.
legacy_unverified · Source version not recorded · locator unknown
The bill page shows H.R. 7391, introduced in the House on February 5, 2026, with Emanuel Cleaver listed among the bill's supporters/cosponsors and referral to the Committee on Energy and Commerce. The measure addresses drug pricing for community health centers by limiting covered outpatient drug prices to the 340B ceiling price at purchase.
legacy_unverified · Source version not recorded · locator unknown
Congress.gov lists H.R.7391 as the Community Health Center Drug Pricing Protection Act, introduced February 5, 2026, with Emanuel Cleaver as an original cosponsor. The official title would ensure federally qualified health centers are not required to pay more than the 340B ceiling price for covered outpatient drugs at purchase. The latest action remains referral to the House Energy and Commerce Committee, so it has not become law.
legacy_unverified · Source version not recorded · locator unknown
GovInfo's Congressional Record Index entry for Emanuel Cleaver lists, under bills and resolutions cosponsored, H.R.7391: a Department of Health and Human Services bill to ensure federally qualified health centers are not required to pay more than the 340B ceiling price for covered outpatient drugs at purchase, with the index reference dated February 5, 2026.
Assessments
Cleaver is an active federal officeholder, and the promise was framed as continuing to fight for lower prescription drug costs rather than guaranteeing enactment of a specific price-reduction law. During the same congressional term, he was an original cosponsor of H.R.7391, a drug-pricing bill aimed at protecting federally qualified health centers from paying above the 340B ceiling price, and was also connected to PBM reform legislation. H.R.7391 remained referred in committee and was not itself enacted, so this is delivery of the advocacy/fighting promise, not proof that prescription drug costs were broadly lowered.
The promise was framed as continuing to fight for lower prescription drug costs, not guaranteeing enactment of a specific bill or a measurable price reduction. In the same federal office context, Cleaver is credited with concrete aligned legislative activity, including support for drug-pricing-related measures such as H.R. 7391 and PBM reform efforts. The cited evidence does not show those 119th Congress bills becoming law or independently proving lower costs, so the delivery rests on fulfilling the advocacy/action promise rather than completing a specific policy outcome.